Waldenstrom Macroglobulinemia clinical trials

Explore recruiting waldenstrom macroglobulinemia clinical trials.

Recruiting waldenstrom macroglobulinemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Waldenstrom Macroglobulinemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)

Greece, France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) – Substudy A – Relapsed/Refractory Waldenstrom Macroglobulinemia

Netherlands, Spain, Germany, Sweden, France, Austria +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients previously treated for Waldenström macroglobulinemia"

France

Therapeutic exploratory (Phase II) EU CTIS Study details

ZANUBRUTINIB, A SECOND GENERATION BTK INHIBITOR, IN ANTI-MAG ANTIBODY NEUROPATHY: A PHASE II ITALIAN MULTICENTER CLINICAL TRIAL (MAZINGA)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Poland, Czechia, Spain, Hungary, Italy, France +1 more

Therapeutic use (Phase IV) EU CTIS Study details

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Netherlands, France, Italy, Spain, Poland

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Waldenstrom Macroglobulinemia trials by city

Waldenstrom Macroglobulinemia in Toronto Waldenstrom Macroglobulinemia in Vancouver Waldenstrom Macroglobulinemia in Montreal Waldenstrom Macroglobulinemia in Calgary Waldenstrom Macroglobulinemia in Edmonton Waldenstrom Macroglobulinemia in Ottawa Waldenstrom Macroglobulinemia in Winnipeg Waldenstrom Macroglobulinemia in Quebec City Waldenstrom Macroglobulinemia in Hamilton Waldenstrom Macroglobulinemia in Kitchener Waldenstrom Macroglobulinemia in London Waldenstrom Macroglobulinemia in Halifax Waldenstrom Macroglobulinemia in New York Waldenstrom Macroglobulinemia in Los Angeles Waldenstrom Macroglobulinemia in Chicago Waldenstrom Macroglobulinemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease